Shots: The marketing authorization is based on P-III ExteNET study results assessing Nerlynx following adjuvant trastuzumab therapy vs PBO in 2,840 patients with early-stage HER2-positive breast cancer within two of […]readmore
Tags : (neratinib)
Shots: The P-III NALA trial involves assessing of neratinib + capecitabine vs Tykerb (lapatinib) + capecitabine in 621 patients in ratio (1:1) with 3L HER2-positive metastatic breast cancer P-III NALA […]readmore
Shots: Puma to receive upfront, milestones up to $7.2M and royalties on sales in Canada. Knight to get exclusive commercialization rights for Nerlynx and will also be responsible for its […]readmore
Shots: The P-III NALA Trial involves assessing of Neratinib + capecitabine vs Tykerb (lapatinib) + capecitabine in 621 patients in ratio (1:1) with HER2-Positive Metastatic Breast Cancer The P-III NALA Trial demonstrated improvement in […]readmore